Want to see AU:CHM full AI Analyst Report?
CHM Stock Chart & Stats
AU$0.01
<AU$0.01(5.13%)
At close: 4:00 PM EDT
AU$0.01
<AU$0.01(5.13%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.24
Previous CloseN/A
Volume45.00K
Average Volume (3M)1.00M
Market Cap
AU$892.01K
Enterprise ValueAU$3.44
Total Cash (Recent Filing)AU$2.50M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Feb 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding81,091,610
10 Day Avg. Volume2,609,837
30 Day Avg. Volume1,002,520
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.26
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$480.58M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageAbsence of reported debt in 2025 reduces fixed financing obligations and default risk, preserving flexibility to allocate cash to R&D or clinical programs. Structurally, low leverage eases near-term liquidity stress and supports pursuing partnerships or staged financing over the next several months.
Strong Gross MarginsHigh reported gross margins indicate favorable unit economics on recorded revenues, suggesting the company’s core activities can scale profitably once revenues grow. Over a 2–6 month horizon, strong gross margins improve the odds that incremental revenue and licensing deals produce durable margin expansion.
Focused CAR‑T PlatformA dedicated CAR‑T and cell therapy focus aligns with a durable, growing oncology market and creates a specialized technical moat. Platform concentration supports deep R&D expertise, increases attractiveness for strategic partnerships, and targets a large addressable market that sustains relevance beyond short-term cycles.
Bears Say
Persistent Cash BurnConsistent negative operating and trailing free cash flow signal ongoing cash burn to fund development and operations. Structurally, this necessitates external financing or partnerships within months, elevating dilution risk, constraining discretionary spending, and limiting autonomous execution of clinical plans.
Shrinking Equity CushionA material decline in shareholders’ equity dramatically reduces the company’s capital buffer against continued losses. This structural deterioration shortens runway, increases sensitivity to funding shocks, and makes urgent equity raises or dilutive financing more likely in the medium term, constraining strategic optionality.
Sustained UnprofitabilityPersistently negative EBIT and net margins reflect that operations still consume capital rather than generate returns. Over 2–6 months this entrenched unprofitability means reliance on external capital or partners until clinical progress converts to revenue, limiting ability to self-fund growth or R&D expansion.
Chimeric Therapeutics Ltd. News
CHM FAQ
What was Chimeric Therapeutics Ltd.’s price range in the past 12 months?
Chimeric Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.24 in the past 12 months.
What is Chimeric Therapeutics Ltd.’s market cap?
Chimeric Therapeutics Ltd.’s market cap is AU$892.01K.
When is Chimeric Therapeutics Ltd.’s upcoming earnings report date?
Chimeric Therapeutics Ltd.’s upcoming earnings report date is Feb 26, 2027 which is in 176 days.
How were Chimeric Therapeutics Ltd.’s earnings last quarter?
Chimeric Therapeutics Ltd. released its earnings results on Aug 28, 2026. The company reported -AU$0.606 earnings per share for the quarter.
Is Chimeric Therapeutics Ltd. overvalued?
According to Wall Street analysts Chimeric Therapeutics Ltd.’s price is currently Overvalued.
Does Chimeric Therapeutics Ltd. pay dividends?
Chimeric Therapeutics Ltd. does not currently pay dividends.
What is Chimeric Therapeutics Ltd.’s EPS estimate?
Chimeric Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chimeric Therapeutics Ltd. have?
Chimeric Therapeutics Ltd. has 81,091,610 shares outstanding.
What happened to Chimeric Therapeutics Ltd.’s price movement after its last earnings report?
Chimeric Therapeutics Ltd. reported an EPS of -AU$0.606 in its last earnings report. Following the earnings report the stock price went up 6.303%.
Which hedge fund is a major shareholder of Chimeric Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:CHM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Chimeric Therapeutics Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CHM Sentiment 88%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-94.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is an Australian clinical-stage biopharmaceutical firm dedicated to developing and commercializing a diverse array of cell therapies designed to combat various cancers. Its lead natural killer (NK) cell platform, CHM 0201, is currently undergoing Phase I clinical evaluation for both solid tumors and hematological malignancies. Another key candidate, CHM 1101 (a CLTX CAR T therapy), is also in Phase I trials, specifically targeting recurrent or progressive glioblastoma in patients expressing MMP2+. Beyond these, the company's development pipeline encompasses CHM 0301 for blood cancers; CLTX CAR NK (CHM 1301) and CDH17 CAR NK (CHM 2301) for solid tumors. The CLTX CAR T platform (CHM 1101) is additionally being investigated for melanoma, colorectal, and prostate cancers, while CDH17 CAR T (CHM 2101) is being developed for neuroendocrine, colorectal, pancreatic, and gastric cancers. Chimeric Therapeutics, headquartered in Carlton, Australia, was founded in 2020.
Technical Analysis
Imugene
―
Living Cell Technologies
―
Mesoblast Limited
―
Immutep Ltd
―
Regeneus Ltd.
―